Credit Suisse Maintains Neutral on Maravai LifeSciences, Lowers Price Target to $11
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Dan Leonard has maintained a Neutral rating on Maravai LifeSciences (NASDAQ:MRVI) and lowered the price target from $14 to $11.
August 08, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Credit Suisse has maintained a Neutral rating on Maravai LifeSciences and lowered the price target from $14 to $11.
The lowering of the price target by Credit Suisse indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Maravai LifeSciences' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100